RUNX3 and ovarian carcinoma: An example of this is the study carried out by Guo et al. [18] in which RUNX3 promoter hypermethylation, which results in RUNX3 inactivation and decreased RUNX3 protein expression, has been identified in the 18 of 30 (60%) patients with endometriosis-associated ovarian carcinoma (EAOC).